[Reversible cardiac valve abnormalities with pergolide treatment]

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Pergolide is a dopamine agonist used to treat Parkinson's disease.
• Fibrotic complications, including retroperitoneal and pleural fibrosis, have been associated with pergolide use.
• Valvulopathy has not been previously reported in association with pergolide.

Observation:

• A patient with Parkinson's disease treated with pergolide developed aortic and mitral regurgitation.
• The patient also presented with pulmonary hypertension.
• Cardiac symptoms resolved after discontinuation of pergolide therapy.

Findings:

• This case report suggests a potential link between pergolide and the development of cardiac valvulopathy.
• The findings indicate that pergolide may induce or exacerbate valvular heart disease and pulmonary hypertension.
• This is one of the first reports linking pergolide to valvulopathy, following three similar cases in late 2002.

Implications:

• Clinicians should be aware of the potential cardiac risks associated with pergolide treatment.
• Monitoring for cardiac valvulopathy and pulmonary hypertension is crucial in patients receiving pergolide.
• Further research is warranted to elucidate the mechanism of pergolide-induced valvulopathy.